Leading medical benefit drugs by commercial PMPM spending U.S. 2022
In 2022, commercial insurance spending on the drug Remicade was at 1.42 U.S. dollars per member per month (PMPM) in the United States. This statistic illustrates the leading medical benefit drugs in the United States, based on PMPM spending.